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Abstract
This brief communication provides information to those developing
monitoring plans for serious adverse events (SAE’s) following
regulatory approval of a new drug. In addition, we (1) illustrate
how many patients would need to be treated in order to have high
confidence of seeing at least 1 pre-specified SAE, (2) show that
absence of proof of a SAE is not proof of absence of that SAE, and
(3) identify statistical methodology that could be used for formal
statistical monitoring of SAE’s.

Introduction
Regardless of the efforts of a pharmaceutical company and of
the US Food and Drug Administration (FDA) to identify harmful
side effects prior to regulatory approval of a new drug, it is not
possible to identify all such serious adverse events (SAE’s). There
are many reasons for this; chief among them is the fact that the
number of patients in clinical development programs of new drugs
to prove efficacy are inadequate to detect rare SAE’s. It is therefore
in a company’s best interest to develop a post marketing risk based
monitoring plan (RBMP) of their drug as it is made available to
patients through physician prescriptions after regulatory approval.
In developing a post marketing RBMP for a specific drug,
discussions with the FDA are helpful and essential as are FDA
Guidelines regarding a RBMP. The first four references of this
document provide links to relevant FDA documents. There is a
document [1] that identifies postmarketing requirements and
commitments. Some of the studies listed may be required; others
may be clinical trials a sponsor has committed to conduct – often
conditional on approval.
Another document [2] discusses postmarketing surveillance
programs, which include clinical trials conducted after regulatory
approval to gather additional information on safety as well in some
cases specific questions of efficacy. The FDA maintains a system of
postmarketing surveillance and risk assessment programs to identify
adverse events (AE’s) that did not appear prior and during the drug
approval process. FDA monitors AE’s and uses the information
collected to update drug labeling – and on some occasions to
reevaluate the approval or marketing decision.
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Another document [3] represents current thinking of the FDA
on guidance for industry oversight of clinical Investigations from a
risk-based approach to monitoring. The guidance does not create or
confer any rights for or on any person and does not operate to bind
FDA or the public. A company can use an alternative approach if
the approach satisfies the requirements of the applicable statutes and
regulations. If the company wants to discuss an alternative approach,
they may contact the FDA staff responsible for implementing the
guidance. If the company cannot identify the appropriate FDA staff,
they may call the appropriate number listed on the title page of the
guidance.
Yet another document [4] describes the FDA Adverse Event
Reporting System (FAERS) which is a database that contains
information on adverse event and medication error reports
submitted to FDA. The database is designed to support FDA’s postmarketing safety surveillance program for drug and therapeutic
biologic products. The informatic structure of the FAERS database
adheres to the international safety reporting guidance [5] issued by
the International Conference on Harmonisation ICH E2B. Adverse
events and medication errors are coded to terms in the medical
dictionary for regulatory activities (MEDRA) [6] terminology.
Executing a RBMP for a newly approved drug will require
summarization of individual AE’s, particularly SAE’s as they
accumulate. Table 1, table 2 and table 3 provide relevant information
about AE’s.

Number of Treated Patients needed to have High Confidence
of observing at least 1 AE
Table 1 gives the number of patients that would need to be treated
with a drug in order to have 100(1 - α)% confidence of observing at
least (≥) 1 occurrence of a specific AE given that the true AE rate
among treated patients is P.
For example, if the fraction of a population who would develop
an adverse event upon treatment with a drug at a given dose were
0.1%, one would require 4,604 (Table 1) patients to be treated with
the drug at the given dose in order to have 99% confidence of ob
serving at least one patient with the adverse event. If one required a
greater degree of certainty, say 99.99%, about 10,000 patients would
need to be treated.
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Table 1: Number of Patients requiring Treatment with a Drug to have 100(1 - α)%
Confidence of Observing at least (≥) 1 AE given the true AE rate is P
P \(1-α)
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Monitoring adverse event rates as data accumulates

Table 2: Exact Confidence intervals (95% & 99% CI) on true incidence (P) of a
Rare SAE under various scenarios; n = number treated, nP = expected number
of SAEs, P (X ≥ 1) = Probability of at least 1 SAE among n patients; Outcome =
probable number of SAEs among n patients.
P

n

nP*

P(X ≥ 1)

95% CI

99% CI

Outcome

.001 25

0

0.025

(0;0.1372)

(0;0.1910)

0

50

0

0.049

(0;0.0711)

(0;0.1005)

0

100

0

0.095

(0;0.0362)

(0;0.0516)

0

150

0

0.139

(0;0.0243)

(0;0.0347)

0

250

0

0.221

(0;0.0146)

(0;0.0210)

0

500

0

0.394

(0;0.0074)

(0;0.0105)

0

1000

1

0.632

(0;0.0037)

(0;0.0053)

0

1000

1

0.632

(0;0.0056)

(0;0.0074)

1

10,000 10

0.99996

(0;0.0004)

(0;0.0005)

0

10,000 10

0.99996

(0.0002;0.0012)

(0.0001;0.0014) 5

10,000 10

0.99996

(0.0005;0.0018)

(0.0040;0.0021) 10

Table 3: Exact Confidence intervals (95% & 99% CI) on true incidence (P) of a
Rare SAE under various scenarios; n = number treated, nP = expected number
of SAEs, P (X ≥ 1) = Probability of at least 1 SAE among n patients; Outcome =
probable number of SAEs among n patients.
P

n

nP* P(X ≥ 1)

95% CI

99% CI

Early on in the monitoring for adverse events (AE’s) of a newly
approved drug, it is unlikely to have even 1 report of a rare serious
adverse event (SAE). For example out of the first 150 patients exposed
to the drug, the probability of observing no patient with an adverse
event given that the true incidence in the population is 0.1% is 0.861.
It is therefore likely that among 150 patients treated with the drug,
there is an observed incidence of 0% (0/150). An exact 95% confidence
interval [7] based on the 0/150 data ranges from 0% to 2.43% (Table 2
and Table 3). If what was known about the mechanism of action, the
pharmacology and/or toxicology of the drug suggested certain unto
ward adverse events were possible, and one monitored specifically for
such events, the fact that no such events were observed among 150
treated patients does not mean that the true incidence of such events
is 0 – since the upper limit of the 95% confidence interval is 2.4%. As
Dr. Paul Leber (former head of the CNS medical Review Division at
FDA) often said “Absence of proof is not proof of absence”.

Outcome

.005 25

0

0.118

(0;0.1372)

(0;0.1910)

0

50

0

0.222

(0;0.0711)
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0

100

0

0.394

(0;0.0362)

(0;0.0516)

0

150

0

0.529

(0;0.0243)

(0;0.0347)

0

150

0

0.529

(0;0.0366)

(0;0.0485)

1

250

1.25 0.714

(0;0.0146)

(0;0.0210)

0

250

1.25 0.714

(0.0001;0.0221)

(0;0.0293)

1

500

2.50 0.918

(0;0.0074)

(0;0.0105)

0
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2.50 0.918

(0.0001;0.0111)

(0;0.0148)

1
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2.50 0.918

(0.0005;0.0144)

(0.0002;0.0184)

2

1,000

5

0.993

(0;0.0037)

(0;0.0053)

0

1,000

5

0.993

(0.0016;0.0116)

(0.0011;0.0141)

5

10,000 50

0.99999 (0;0.0004)

(0;0.0005)

0

10,000 50

0.99999 (0.0016;0.0037)

(0.0014:0.0041)

25

10,000 50

0.99999 (0.0037;0.0066)

(0.0034;0.0071)

50

Table 1 illustrates how many patients would need to be treated
before one has high confidence of seeing at least one rare AE. Table
2 and table 3 illustrate that zero occurrences of an AE of interest
from patients treated in the post marketing life of a compound
does not allow one to conclude that the incidence of that AE is zero.
For example, from table 3, 0 SAEs among 1,000 patients treated is
consistent with the true SAE rate being as high as 0.37% with 95%
confidence and as high as 0.53% with 99% confidence.
Procedures exist that permit formal sequential, statistical
monitoring of AE’s of a drug in post-marketing as data accumulate
(spontaneous reports). The methods of Schultz et al. [8], Fleming
[9,10], Coe and Tamhane [11] or Peace [12,13] or Jennison and
Turnbull [14] may be adapted for monitoring post-marketing AE’s.
There are challenges in doing this: (1) the referenced procedures
were developed for group sequential monitoring given a fixed,
specified total number of patients to be treated. The analyses are to be
conducted at each of a fixed number of stages, where the number of
patients accrued between stages is usually taken to be the total number
of patients to be treated divided by the number of analysis stages.
Clearly in monitoring post-marketing AE’s the number of patients
to be treated is not known nor is it fixed. However, for monitoring
purposes, one could develop a statistical monitoring plan based on
a targeted number of patients to be treated within specified intervals
of time. The intervals may be more frequent in the first year of postmarketing say, than in subsequent years. (2) Other challenges are
what are the numerator and denominator of the incidence estimate at
any particular point in time? This will require the company to use its
own spontaneous reporting system as well as the FDA adverse event
reporting system (FAERS).

Summary
This commentary has provided information to those developing
monitoring plans for SAE’s following regulatory approval of a new
drug. In addition, we have (1) illustrated how many patients would
need to be treated in order to have high confidence of seeing at least
1 pre-specified SAE, (2) shown that absence of proof of a SAE is not
proof of absence of that SAE, and (3) identified methodology that
could be used for formal statistical monitoring.
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